TenNor of Suzhou Raises $25 Million for Dual-Action Antibiotics

TenNor Therapeutics of Suzhou announced a $25 million Series B financing led by Northern Light Venture Capital. TenNor is developing novel dual-acting antibiotics for unmet needs.The company's lead product, TNP-2092, is an oral capsule that treats  gastrointestinal tract bacterial infections, especially digestive diseases associated with Helicobacter pylori. The funding will be used to support a China Phase III trial of TNP-2092. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.